Prognostic value of glucose fluctuation in patients undergoing thrombolysis or thrombectomy due to acute ischemic stroke

ÇIPLAK S., ADIGÜZEL A., Ozturk U., Akalin Y.

EGYPTIAN JOURNAL OF NEUROLOGY PSYCHIATRY AND NEUROSURGERY, cilt.57, sa.1, 2021 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 57 Sayı: 1
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1186/s41983-021-00416-y
  • Dergi Adı: EGYPTIAN JOURNAL OF NEUROLOGY PSYCHIATRY AND NEUROSURGERY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, Arab World Research Source, EMBASE, Directory of Open Access Journals
  • Anahtar Kelimeler: Acute ischemic stroke, Glucose, Thrombolysis, Thrombectomy, BLOOD-GLUCOSE, HYPERGLYCEMIA, OUTCOMES, ECASS
  • İnönü Üniversitesi Adresli: Evet

Özet

Background Hyperglycemia during acute ischemic stroke is associated with worse outcomes, and this glucose altitude may persist in the initial days. In this study, we investigate the effect of glucose fluctuations in the first 4 days in patients diagnosed with acute ischemic stroke and who underwent ivr-tPA +/- interventional thrombectomy or only interventional thrombectomy on stroke prognosis. Study was designed bicentered retrospective case series. Patients older than 18 years were included and those suitable for acute treatment, treatment indications, contraindications, and treatment management of hyperglycemia were selected according to the 2018 American Stroke Association guidelines. The effect of fasting glucose values of patients in the first 4 days on admission and 24th hour NIHSS scores, duration of hospitalization, disability, mortality, and prognosis were analyzed. We aimed to demostred the effect of the first 4-day glucose values measured in patients treated in a stroke center on clinical prospect. Results One hundred and seventy-six patients were included in the study. Group 1 included 30 (17%) patients with severe clinical condition (NIHSS at admission >= 16), and Group 2 comprised 146 (83%) patients with moderate and mild clinical condition (NIHSS at admission < 16). The glucose values of Groups 1 and 2 were found as follows: day 1 (admission): 178.7 +/- 10.3 mg/dl and 138.3 +/- 54.9 mg/dl, day 2: 197.7 +/- 99.8 mg/dl and 137.6 +/- 51.8 mg/dl, day 3: 186.1 +/- 97.6 mg/dl and 127.5 +/- 50.0 mg/dl, and day 4: 169.2 +/- 85.0 mg/dl and 126.7 +/- 49.3 mg/dl (p < 0.05). Mortality risk of patients with glucose >= 200 mg/dl was 43.5% on day 1 (p > 0.05), 57.1% on day 2, 68.4% on day 3, and 76.5% on day 4 (p < 0.05). Conclusions The glucose level of patients in severe clinical condition peaked on the second day and that 4 days of resilient severe hyperglycemia is a negative risk factor for sequela and mortality.